Trial Profile
Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Apr 2019
Price :
$35
*
At a glance
- Drugs Antisense K-ras RNA gene therapy (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors Silenseed
- 13 Feb 2014 New trial record
- 04 Jun 2013 Results were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in June 2013.